Fig. 2.

Somatic VHL and DDR alterations are associated with treatment outcome and PFS in 56 patients with first-line VEGF-TKI therapy. (A) DDR genomic alteration oncoplot of 56 patients. A total of 30 DDR gene alterations were detected in 17 patients. (B) Distribution of deleterious somatic and germline alterations and CNVs (amplifications and deletions) in patients with mccRcc. (C) Comparison of the ORR percentages of the DDR pathway mutant group and the nonmutant group. DDR mutant patients tended to show a better ORR rate than the nonmutant patients. (D-F) Kaplan–Meier plots were used to estimate PFS according to DDR alteration, VHL mutation and co-mutation status. Patients harboring VHL mutations, DDR alterations or VHL and DDR co-mutations showed a longer PFS than the corresponding nonmutation patients in first-line TKI treatment (log-rank p = 0.04, 0.017, 0.011)